The global Anakinra market has been witnessing substantial growth and is expected to continue expanding over the coming years. Anakinra, an interleukin-1 receptor antagonist, is primarily used for treating autoimmune diseases, including rheumatoid arthritis, and has shown effectiveness in conditions like systemic juvenile idiopathic arthritis and more recently, in the management of COVID-19 related inflammation. As per Dataintelo’s recent market research report, the Anakinra market is expected to grow at a healthy CAGR of 7.5% from 2025 to 2030, reaching an estimated value of USD 4.3 billion by the end of the forecast period. The increasing adoption of biologics and the shift towards personalized medicine are further propelling the demand for Anakinra in various therapeutic areas.